Brief: Calliditas Therapeutics Q2 Adj Oper Profit At SEK 70.2 Mln
13/08/2024 06:07
Aug 13 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* TOTAL NET SALES FROM NEFECON FRANCHISE, INCLUDING
MILESTONES,
ARE ESTIMATED TO BE USD 165-185 MILLION FOR YEAR ENDING DECEMBER
31, 2024
* Q2 ADJUSTED OPERATING PROFIT AMOUNTED TO SEK 70.2 MILLION
Source text for Eikon: ID:nWkr8ZKkFb
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations